TG Therapeutics Stock Rises Thursday: What's Driving The Gains?

Benzinga_recent_news06-19

TG Therapeutics reported positive Phase 1 results for subcutaneous BRIUMVI (ublituximab-xiiy) in myasthenia gravis, with 82% of subjects hitting a minimal clinically important difference in MG-ADL and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644315880?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/18/TG-Therapeutics-Photo-by-Piotr-Swat-via-.jpeg","is_english":true,"pubTime":"2026-06-19 03:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644315880","market":"us","top_or_hot":-1,"title":"TG Therapeutics Stock Rises Thursday: What's Driving The Gains?","media":"Benzinga_recent_news","content":"<div>\n<p>TG Therapeutics reported positive Phase 1 results for subcutaneous BRIUMVI (ublituximab-xiiy) in myasthenia gravis, with 82% of subjects hitting a minimal clinically important difference in MG-ADL and...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/06/53289968/tg-therapeutics-stock-rises-thursday-whats-driving-the-gains\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TG Therapeutics Stock Rises Thursday: What's Driving The Gains?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTG Therapeutics Stock Rises Thursday: What's Driving The Gains?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-19 03:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/movers/26/06/53289968/tg-therapeutics-stock-rises-thursday-whats-driving-the-gains><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TG Therapeutics reported positive Phase 1 results for subcutaneous BRIUMVI (ublituximab-xiiy) in myasthenia gravis, with 82% of subjects hitting a minimal clinically important difference in MG-ADL and...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/movers/26/06/53289968/tg-therapeutics-stock-rises-thursday-whats-driving-the-gains\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4090","symbol_name":"商品化工","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/06/53289968/tg-therapeutics-stock-rises-thursday-whats-driving-the-gains","article_id":"2644315880","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/18/TG-Therapeutics-Photo-by-Piotr-Swat-via-.jpeg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/06/53289968/tg-therapeutics-stock-rises-thursday-whats-driving-the-gains","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2644315880","pubTimestamp":1781810940,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"TG Therapeutics shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4090":"商品化工","TGTX":"TG Therapeutics Inc.","BK4588":"碎股","TG":"特里迪加","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4153":"铝"},"translate_title":"TG Therapeutics股价周四上涨：是什么推动了上涨？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1.5,"TG":1.5},"content_text":"TG Therapeutics reported positive Phase 1 results for subcutaneous BRIUMVI (ublituximab-xiiy) in myasthenia gravis, with 82% of subjects hitting a minimal clinically important difference in MG-ADL and a mean improvement of over four points. \nManagement also said it plans to start a Phase 2 trial enrolling about 120 patients, aiming to pair rapid symptom control with longer-term disease modification.\nWith markets open, the broader tone is supportive for risk: the Nasdaq-100 is up 2.22% and the Russell 2000 is up 1.48%, even though market breadth is mixed (an advance/decline ratio of 0.8). That backdrop matters because TGTX is outperforming on a day when its sector is a drag, which usually points back to company-specific news flow.\nThe longer-term trend remains firmly bullish: the stock is trading 23.4% above its 20-day SMA ($42.46) and 56.3% above its 200-day SMA ($33.53), and it's still benefiting from the golden cross that formed in April. The trade-off is that this kind of extension can amplify pullbacks if momentum cools, especially near prior breakout areas.\nRSI is the cleaner momentum lens right now, and at 81.03 it's in overbought territory—basically a \"stretched\" reading that often shows buyers have been aggressive and the stock may need to pause or digest. If you want a secondary check, MACD remains in a bullish posture (above its signal line), which typically supports \"buy-the-dip\" behavior until that relationship flips.\nTG Therapeutics is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. It already has FDA approval for BRIUMVI (ublituximab-xiiy) to treat adults with relapsing forms of multiple sclerosis, and it also has approvals outside the U.S. for RMS in patients with active disease.\nThat matters for today's move because the market is reacting to pipeline expansion around BRIUMVI—specifically the subcutaneous program in myasthenia gravis and the company's plan to advance into a Phase 2 study. Investors are also tracking the Phase 3 ENHANCE trial work in MS and the company's stated goal of a supplemental FDA filing in the second half of 2026.\nBelow is the Benzinga Edge scorecard for TG Therapeutics, highlighting its strengths and weaknesses compared to the broader market:\nThe Verdict: TG Therapeutics’ Benzinga Edge signal reveals a momentum-driven story with price strength doing most of the talking right now. For longer-term holders, the key risk is that momentum can cool quickly when the stock is extended, so the next pullback toward trend support may matter as much as the next headline.\nTGTX Stock Price Activity: TG Therapeutics shares were up 1.09% at $52.06 at the time of publication on Thursday, according to Benzinga Pro data.\nImage: Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644315880","isCrawlerRequest":true}